Umeclidinium bromide

Umeclidinium bromide, sold under the brand name Incruse Ellipta, is a long-acting muscarinic antagonist approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It is also approved for this indication in combination with vilanterol (as umeclidinium bromide/vilanterol) and also as a triple-therapy combination as fluticasone furoate/umeclidinium bromide/vilanterol.

It is on the World Health Organization's List of Essential Medicines. In 2020, it was the 245th most commonly prescribed medication in the United States, with more than 1million prescriptions.